RNAi Agents for Mosquito Virus Transmission Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for controlling mosquito-borne viruses like dengue, Zika, and Chikungunya are limited, especially as traditional methods face challenges due to urbanization, globalization, and insecticide resistance, and the stability of Wolbachia-mediated blocking phenotypes over time is uncertain.
Innovation Solution
The use of RNA interference (RNAi) to inhibit the expression of specific mosquito genes, such as alpha-mannosidase 2 and Cadherin87A, either alone or in combination, in Aedes aegypti mosquitoes, either by direct injection, recombinant vectors, or bacteria modified to express RNAi agents, to reduce viral load and transmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Wolbachia bacteria are introduced into mosquitoes to block virus transmission, then viral transmission is reduced, but the blocking phenotype stability over time is uncertain
Solution Approach 1:
The patent uses RNAi agents as intermediaries to mediate the blocking of virus transmission. Instead of relying on Wolbachia bacteria as the primary blocking mechanism, the patent introduces RNAi agents that specifically target and silence mosquito genes involved in virus replication and transmission, providing a more stable and controllable blocking effect
Solution Approach 2:
The patent changes the biological parameter by using gene silencing through RNAi to achieve virus blocking. By targeting specific mosquito genes (such as those involved in virus entry, replication, or assembly) with RNAi agents, the patent creates a stable blocking phenotype that does not rely on the uncertain stability of Wolbachia infection over time
2Productivity
If traditional mosquito control methods are used, then mosquito populations are reduced, but insecticide resistance and urbanization make these methods increasingly difficult
Solution Approach 1:
The patent replaces the mechanical/chemical approach of insecticide application with a biological approach using RNAi technology. Instead of using chemicals that mosquitoes can develop resistance to, the patent uses gene-specific RNAi agents that silence essential mosquito genes, creating a more adaptable control method that remains effective despite urbanization and insecticide resistance
Solution Approach 2:
The RNAi agents work by triggering the mosquito's own RNA interference machinery to silence target genes. This self-service mechanism uses the mosquito's endogenous biological systems against it, providing a sustainable control approach that does not rely on external chemical inputs and can maintain effectiveness in changing environmental conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces viral load in mosquitoes and their ability to transmit viruses to mammalian hosts, providing a stable and long-term solution for controlling mosquito-borne virus transmission.
Implementation Method 1
RNA interference (RNAi) is used to inhibit expression of one or more mosquito genes
Data Source
AI summary
Provided are compositions and methods for inhibiting transmission of viruses that use mosquitoes as vectors, such as dengue (DENV), Zika (ZIKV) and Chikungunya (CHIKV) viruses. Inhibiting transmission includes reducing viral load of the virus in mosquitoes. The viral load is reduced in mosquitoes that are exposed to the virus by introducing into the mosquitoes or mosquito larvae one or more agents that can participate in RNA interference (RNAi) of expression of one or more mosquito genes, such as alpha-mannosidase 2, or Cadherin87A, or a combination thereof. Also provided are modified mosquitoes or mosquito larvae that comprise the RNAi agents. The modified mosquitoes can be released into a population of unmodified mosquitoes to inhibit transmission of the virus between mammalian hosts. Also provided are compositions comprising an RNAi agent or an expression vector that encodes the RNAi agent for use in the described methods.